Paris-based digital health insurance startup Alan raised €100M led by Index Ventures at a €5B valuation, up from €4B after raising €173M in September 2024
30% of European unicorns may have lost their billion-dollar status, but not Alan.
Context & Ripple Effects
Alan’s €5B valuation builds on its €173M round at a €4B valuation in September 2024, extending a funding history that began with a SaaS offering for France’s private insurance market and later added personalized mental-health programs.
The round stands out in coverage that says some European unicorns have fallen below the $1B threshold. Subsequent coverage of Alan’s €480M raise at a €5.5B valuation suggests this financing was part of continued investor support rather than a one-off valuation defense.
First-order effects
- Alan gains €100M of new financing and a €5B private-market valuation, while Index Ventures becomes the lead investor in the round.
- The company preserves and strengthens its unicorn standing at a time when the article describes broader pressure on European late-stage valuations.
Second-order effects
- The valuation step-up gives Alan a stronger benchmark for future fundraising and a clearer signal to employees, customers, and prospective partners that investors continue to support its digital-health-insurance model.
- Other European digital-health and insurance startups seeking late-stage capital will face a sharper distinction between businesses able to show comparable investor conviction and those raising in a more skeptical market.
Third-order effects
- If repeat financings continue to concentrate in a small group of established European insurtechs, the sector could become more polarized: well-capitalized platforms gain room to invest while weaker unicorns struggle to sustain prior valuations.
- The pattern points toward private-market valuations being increasingly determined by company-specific momentum rather than the unicorn label alone, though broader funding conditions can still alter that balance.
The trend: European late-stage funding is becoming more selective, with resilient digital-health platforms still able to raise at higher valuations despite pressure on the wider unicorn cohort.